Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
Sign Up to like & getrecommendations! Published in 2017 at "Thrombosis and haemostasis"
DOI: 10.1160/th17-03-0193
Abstract: Currently, low molecular weight heparin (LMWH) is the guideline endorsed treatment of patients with cancer associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, there are limited data supporting its… read more here.
Keywords: trial; adam vte; thromboembolism; venous thromboembolism ... See more keywords